The UCLA CLINICAL SCIENTIST TRAINING PROGRAM IN CANCER GENE MEDICINE (K12 CA 76995) has served for six years as a training vehicle for clinical scholars in patient-oriented cancer gene medicine translational and clinical research. This training program has matured significantly in the previous funding period due, in part, to a significant expansion of the cancer efforts in the UCLA Human Gene Medicine Program. To date, 235 patients (91% cancer) have been enrolled in 32 FDA-approved trials using various strategies for the treatment of melanoma, renal and prostate cancer, ovarian carcinoma, CNS tumors, lung cancer and hepatocellular carcinoma. The HGMP subjects all gene medicine trials to multiple overlapping levels of scientific and compliance oversight, and supervises a Level 3 GMP Gene Therapy Core Laboratory. This K12 training grant trains MD fellows in clinical aspects of cancer gene medicine with an emphasis on bridging basic and clinical research, the design and conduct of hypothesis-driven trials, and-in depth didactic training and exposure to institutional and federal regulatory oversight mechanisms and approved processes. This training program has integrated enhanced training in the ethical conduct of cancer gene medicine clinical research. The educational infrastructure has been significantly enhanced to include formal training and certification by the UCLA HGMP/IRB for clinical trials participation, clinical data safety monitoring, mechanisms for submission of IND applications to the FDA and the basic science of gene medicine. In the last funding cycle, this K12 has supported 12 trainees from five oncology disciplines (Medical, Surgical, Thoracic, Urologic and Pediatric) and is represented by seven males (one African-American) and five females. All 12 have remained in acacemic medicine, five have secured tenure-track faculty positions and seven are completing their training. We request support to continue accepting two fellows per year for another five year period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA076905-09
Application #
7116526
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
1997-09-30
Project End
2008-06-30
Budget Start
2006-09-20
Budget End
2007-06-30
Support Year
9
Fiscal Year
2006
Total Cost
$508,680
Indirect Cost
Name
University of California Los Angeles
Department
Surgery
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lasky 3rd, Joseph L; Panosyan, Eduard H; Plant, Ashley et al. (2013) Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 33:2047-56
Sawey, Eric T; Chanrion, Maia; Cai, Chunlin et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19:347-58
Finn, Richard S; Bentley, Greg; Britten, Carolyn D et al. (2009) Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 29:284-90
Lukacs, R U; Lawson, D A; Xin, L et al. (2008) Epithelial stem cells of the prostate and their role in cancer progression. Cold Spring Harb Symp Quant Biol 73:491-502
Lee, Jay M; Yanagawa, Jane; Peebles, Katherine A et al. (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66:208-17
Peebles, Katherine A; Lee, Jay M; Mao, Jenny T et al. (2007) Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 7:1405-21
Memarzadeh, Sanaz; Xin, Li; Mulholland, David J et al. (2007) Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12:572-85
Lasky, Joseph L; Liau, Linda M (2006) Targeting stem cells in brain tumors. Technol Cancer Res Treat 5:251-60
Schumacher, Lana Y; Vo, Dan D; Garban, Hermes J et al. (2006) Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 176:4757-65
Ribas, Antoni; Vo, Dan D; Weeks, David L et al. (2006) Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother 55:663-71

Showing the most recent 10 out of 29 publications